日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial

在未感染 HIV 的健康成人中,采用 C 亚型 ALVAC-HIV (vCP2438) 疫苗初免联合二价 C 亚型 gp120 疫苗加强免疫(佐剂为 MF59 或明矾)的安全性和免疫原性:一项 1/2a 期随机试验 (HVTN 107)

Moodie, Zoe; Andersen-Nissen, Erica; Grunenberg, Nicole; Dintwe, One B; Omar, Faatima Laher; Kee, Jia J; Bekker, Linda-Gail; Laher, Fatima; Naicker, Nivashnee; Jani, Ilesh; Mgodi, Nyaradzo M; Hunidzarira, Portia; Sebe, Modulakgota; Miner, Maurine D; Polakowski, Laura; Ramirez, Shelly; Nebergall, Michelle; Takuva, Simbarashe; Sikhosana, Lerato; Heptinstall, Jack; Seaton, Kelly E; De Rosa, Stephen; Diazgranados, Carlos A; Koutsoukos, Marguerite; Van Der Meeren, Olivier; Barnett, Susan W; Kanesa-Thasan, Niranjan; Kublin, James G; Tomaras, Georgia D; McElrath, M Juliana; Corey, Lawrence; Mngadi, Kathryn; Goepfert, Paul